CervoMed Completes Enrollment In Phase 2A Study Of Neflamapimod For nfvPPA, Type Of Frontotemporal Dementia; First Biomarker Data Expected In Early Q4 Of 2026 And The First Clinical Data In Q1 2027

뉴스 본문을 불러오고 있어요.

CervoMed Completes Enrollment In Phase 2A Study Of Neflamapimod For nfvPPA, Type Of Frontotemporal Dementia; First Biomarker Data Expected In Early Q4 Of 2026 And The First Clinical Data In Q1 2027 | 웨이프 WAPE

CervoMed Completes Enrollment In Phase 2A Study Of Neflamapimod For nfvPPA, Type Of Frontotemporal Dementia; First Biomarker Data Expected In Early Q4 Of 2026 And The First Clinical Data In Q1 2027

기사 요약

관련 종목

댓글 —